Details of the Drug

General Information of Drug (ID: DMQNMAT)

Drug Name
Tirzepatide
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Approved [1]
ATC Code
A10BX16: Tirzepatide
A10BX: Other blood glucose lowering drugs, excl. insulins
A10B: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10: DRUGS USED IN DIABETES
A: ALIMENTARY TRACT AND METABOLISM
Cross-matching ID
PubChem CID
163285897
UNII
OYN3CCI6QE
DrugBank ID
DB15171
TTD ID
DA69JF

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric inhibitory polypeptide receptor (GIPR) TTYMKBE GIPR_HUMAN Agonist [2]
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 05 Endocrine, nutritional or metabolic disease
Disease Class ICD-11: 5A11 Type 2 diabetes mellitus
The Studied Tissue Liver tissue
The Studied Disease Type 2 diabetes [ICD-11:5A11]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 1.25E-01 0.17 1.26
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215866.
2 Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.